COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS CHEMOTHERAPY VS CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER IN JAPAN

被引：0
|
作者：
Morimoto, K. [1 ]
Moriwaki, K. [2 ]
Shimozuma, K. [3 ]
Nakayama, T. [1 ]
机构：
[1] Kyoto Univ, Kyoto, Japan
[2] Ritsumeikan Univ, Kyoto 26, Japan
[3] Ritsumeikan Univ, Kusatsu, Japan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA7
引用
收藏
页码：S505 / S505
页数：1
相关论文
共 50 条
  • [31] Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer
    K. Zhou
    F. Wen
    P. Zhang
    J. Zhou
    H. Chen
    H. Zheng
    Y. Yang
    Q. Li
    Clinical and Translational Oncology, 2017, 19 : 1117 - 1124
  • [32] Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer
    Zhou, K.
    Wen, F.
    Zhang, P.
    Zhou, J.
    Chen, H.
    Zheng, H.
    Yang, Y.
    Li, Q.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (09): : 1117 - 1124
  • [33] EFFICACY AND COST-EFFECTIVENESS OF SECOND-LINE CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER
    Zhou, K.
    VALUE IN HEALTH, 2017, 20 (09) : A871 - A871
  • [34] EFFICACY AND COST-EFFECTIVENESS OF SECOND-LINE CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER
    Zhou, K.
    VALUE IN HEALTH, 2017, 20 (05) : A92 - A92
  • [35] Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Liu, Xiaoxia
    Li, Yan
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [36] Efficay and safety of chemotherapy plus nivolumab for advanced gastric cancer with ascites
    Matsumoto, T.
    Makiyama, C.
    Nakasya, A.
    Nagai, H.
    Ikoma, T.
    Yasuda, T.
    Boku, S.
    Shibata, N.
    Tsuduki, T.
    Yasui, H.
    Satake, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1369 - S1369
  • [37] Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
    Cai, Hongfu
    Fang, Ling
    Lin, Jingwen
    Zheng, Zhiwei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [38] COST-EFFECTIVENESS OF PALLIATIVE CHEMOTHERAPY IN ADVANCED GASTROINTESTINAL CANCER
    GLIMELIUS, B
    HOFFMAN, K
    GRAF, W
    HAGLUND, U
    NYREN, O
    PAHLMAN, L
    SJODEN, PO
    ANNALS OF ONCOLOGY, 1995, 6 (03) : 267 - 274
  • [39] Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients
    Ohno, Shinya
    Shoji, Ayako
    Hatake, Kiyohiko
    Oya, Naoko
    Igarashi, Ataru
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (10) : 1130 - 1141
  • [40] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system
    Lang, Wenwang
    Deng, Lian
    Lu, Meijun
    Ouyang, Ming
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 1027 - 1042
12345